149 related articles for article (PubMed ID: 7599450)
1. Cost-effectiveness of fracture prevention in established osteoporosis.
Jönsson B; Christiansen C; Johnell O; Hedbrandt J
Osteoporos Int; 1995 Mar; 5(2):136-42. PubMed ID: 7599450
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of fracture prevention in established osteoporosis.
Jönsson B; Christiansen C; Johnell O; Hedbrandt J; Karlsson G
Scand J Rheumatol Suppl; 1996; 103():30-8; discussion 39-40. PubMed ID: 8966488
[TBL] [Abstract][Full Text] [Related]
3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
4. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.
Kanis JA; Johnell O; Oden A; Borgstrom F; Johansson H; De Laet C; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):6-14. PubMed ID: 15103452
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.
Turner DA; Khioe RFS; Shepstone L; Lenaghan E; Cooper C; Gittoes N; Harvey NC; Holland R; Howe A; McCloskey E; O'Neill TW; Torgerson D; Fordham R;
J Bone Miner Res; 2018 May; 33(5):845-851. PubMed ID: 29470854
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
[TBL] [Abstract][Full Text] [Related]
8. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.
King AB; Saag KG; Burge RT; Pisu M; Goel N
Osteoporos Int; 2005 Dec; 16(12):1545-57. PubMed ID: 15942702
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Jansen JP; Gaugris S; Bergman G; Sen SS
Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
[TBL] [Abstract][Full Text] [Related]
11. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?
Sanders KM; Nicholson GC; Watts JJ; Pasco JA; Henry MJ; Kotowicz MA; Seeman E
Bone; 2006 May; 38(5):694-700. PubMed ID: 16507356
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.
Majumdar SR; Lier DA; McAlister FA; Rowe BH; Siminoski K; Hanley DA; Russell AS; Johnson JA
Am J Med; 2013 Feb; 126(2):169.e9-17. PubMed ID: 23331449
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective osteoporosis treatment thresholds: the United States perspective.
Tosteson AN; Melton LJ; Dawson-Hughes B; Baim S; Favus MJ; Khosla S; Lindsay RL;
Osteoporos Int; 2008 Apr; 19(4):437-47. PubMed ID: 18292976
[TBL] [Abstract][Full Text] [Related]
14. Effect and offset of effect of treatments for hip fracture on health outcomes.
Jonsson B; Kanis J; Dawson A; Oden A; Johnell O
Osteoporos Int; 1999; 10(3):193-9. PubMed ID: 10525710
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial.
Majumdar SR; Lier DA; Leslie WD
J Clin Endocrinol Metab; 2013 May; 98(5):1991-2000. PubMed ID: 23596140
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Christensen PM; Brixen K; Gyrd-Hansen D; Kristiansen IS
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):387-96. PubMed ID: 15853932
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
19. Costs and quality of life associated with osteoporosis-related fractures in Sweden.
Borgström F; Zethraeus N; Johnell O; Lidgren L; Ponzer S; Svensson O; Abdon P; Ornstein E; Lunsjö K; Thorngren KG; Sernbo I; Rehnberg C; Jönsson B
Osteoporos Int; 2006; 17(5):637-50. PubMed ID: 16283064
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis.
Ding H; Koinuma N; Stevenson M; Ito M; Monma Y
J Bone Miner Metab; 2008; 26(1):34-41. PubMed ID: 18095061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
